Back

Learner’s Digest International (TM)

  • Breast Neoplasms
  • Neoadjuvant Therapy

Update on Management of HER2-Positive Early Breast Cancer

The goal of this program is to improve management of HER2-positive early breast cancer. After hearing and assimilating this program, the clinician will be better able to:Differentiate among treatment strategies based on tumor characteristics and hormone receptor status.Select appropriate neoadjuvant therapy regimens for locally advanced disease.Manage residual disease after neoadjuvant therapy with targeted agents.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

ABIM — Medical KnowledgeUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Pricing

Membership pricing — $1,095 / year

This provider prices CME through membership. Individual courses may also be sold separately.

See plans on audio-digest.org

Listed by the provider

  • Enduring / On-demand
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • Membership pricing
  • Released
    Sep 1, 2026
  • Last day to claim credit
    Mar 22, 2029 2 years left